Dr Deckster Tonny SAVADYE, CEO of Zimbabwe National Biotechnology Authority (NBA), and Dr Yang Yili, International Centre for Genetic Engineering and Biotechnology China Regional Research Centre (ICGEB), visited Recbio. Dr SAVADYE and his team conducted an on-the-spot investigation of the manufacturing facilities for the COVID-19/Shingles vaccine and HPV vaccine at Recbio. Witnessed by the leaders of Taizhou Pharmaceutical High-tech Industrial Park, the three parties jointly signed a strategic cooperation agreement.

According to the agreement, Recbio will cooperate with ICGEB China Regional Research Center to provide technical support related to vaccine production in Zimbabwe, including personnel training, plant designing, clinical trials, sub-packaging technology, and stock solution technology transfer, etc., with COVID-19 vaccine as the entry point, and gradually expand to other vaccine varieties, contributing to localised vaccine production in Zimbabwe and Africa.

The signing of this contract marks that Recbio vaccine D&G and production technology platform and products have been recognized by more international organisations and countries. Recbio will actively implement the national "Belt and Road Initiative" and seize the overseas market layout of vaccines.

The Zimbabwe National Biotechnology Authority is a government agency established by legislation in 2006 to promote the application of traditional and cutting-edge biotechnology in the fields of medicine, agriculture, and others.